NCT02869516 Institut Paoli Calmettes Acute Leukemia Database
| NCT ID | NCT02869516 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Paoli-Calmettes |
| Condition | Acute Leukemia Diagnosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 27,000 participants |
| Start Date | 1995-01 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 27,000 participants in total. It began in 1995-01 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Database of Institut Paoli-Calmettes patients diagnosed with Acute Leukemia
Eligibility Criteria
Inclusion Criteria: * Patient with a diagnosis of acute leukemia Exclusion Criteria: * Non applicable
Contact & Investigator
Frequently Asked Questions
Who can join the NCT02869516 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Leukemia Diagnosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02869516 currently recruiting?
Yes, NCT02869516 is actively recruiting participants. Contact the research team at drci.up@ipc.unicancer.fr for enrollment information.
Where is the NCT02869516 trial being conducted?
This trial is being conducted at Marseille, France.
Who is sponsoring the NCT02869516 clinical trial?
NCT02869516 is sponsored by Institut Paoli-Calmettes. The trial plans to enroll 27,000 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.